Pharminent

Bristol─Myers Squibb’s Orencia receives European approval for active psoriatic arthritis treatment

Bristol─Myers Squibb Company announced that the European Commission (EC) has approved Orencia alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis (PsA) in adult http://pharmabiz.com/ArticleDetails.aspx?aid=103403&sid=2

Filed under: Arthritis